The Marked Chart Wire · Series of events
Series of events · Oklo
Oklo advances nuclear plans with DOE support and earnings
Oklo secured a DOE initiative, beat earnings estimates, and received clearance for reactor testing.
Updated
The flow in 3 points
- Oklo selected for DOE initiative to produce medical isotopes
- Quarterly revenue of $1.86 million beat estimates by 68 percent
- DOE cleared unrestricted research at Groves-1 reactor
What happened, in order
Times are Eastern-
Where it began
DOE initiative pick
Oklo was selected for the DOE Nuclear Energy Launch Pad initiative to build a Texas facility for medical isotopes.
-
Earnings beat
Oklo reported quarterly revenue of $1.86 million, beating estimates by 68 percent, with an EPS of -$0.22.
Read the story -
Latest
Reactor clearance
The DOE cleared Oklo to conduct unrestricted research and testing at its Groves-1 reactor, which hit first criticality in August 2026.
Read the story
How they connect
Oklo was first selected for a DOE initiative to produce medical isotopes, followed by a quarterly earnings report that beat estimates. The company then received DOE clearance for unrestricted research at its Groves-1 reactor.
The stocks in this series
Prices from Based on Thu, Nov 19 close · Opens Fri 9:30 AM ET. Each tile opens the stock's chart and news.
A series is a short summary of connected news, for learning. Not verified and not advice. Check the full stories before you act.